Avanir Pharmaceuticals (Nasdaq: AVNR) reported earnings on May 8. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q2), Avanir Pharmaceuticals crushed expectations on revenues and missed expectations on earnings per share.

Compared to the prior-year quarter, revenue expanded significantly and GAAP loss per share improved.

Margins grew across the board.

Revenue details
Avanir Pharmaceuticals booked revenue of $10.0 million. The four analysts polled by S&P Capital IQ wanted to see revenue of $7.5 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $1.4 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at -$0.13. The five earnings estimates compiled by S&P Capital IQ anticipated -$0.12 per share. GAAP EPS were -$0.13 for Q2 versus -$0.12 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 94.7%, 270 basis points better than the prior-year quarter. Operating margin was -169.8%, 83,790 basis points better than the prior-year quarter. Net margin was -169.7%, 83,730 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $9.3 million. On the bottom line, the average EPS estimate is -$0.11.

Next year's average estimate for revenue is $32.7 million. The average EPS estimate is -$0.46.

Investor sentiment
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 194 members out of 256 rating the stock outperform, and 62 members rating it underperform. Among 57 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 37 give Avanir Pharmaceuticals a green thumbs-up, and 20 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Avanir Pharmaceuticals is outperform, with an average price target of $5.40.

Over the decades, small-cap stocks like Avanir Pharmaceuticals have produced market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: 2 Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.